Keryx Biopharmaceuticals (KERX) Starts Chronic Kidney Disease Treatment Study iStockAnalyst (By Balaseshan) Keryx Biopharmaceuticals (NASDAQ: KERX) said it has initiated a phase 2 study of Zerenex (ferric citrate) for the treatment of patients with stage 3 to 5 non-dialysis dependent chronic kidney disease (NDD-CKD). Zerenex is the company's ... |
